ReviewFrontiers in immunology2026
When ISG15 is involved in inflammation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial checkpoint for interferon responses in macrophages.Exploration of targeted anti-tumor therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon-stimulated gene 15 (ISG15), a key ubiquitin-like modifying molecule, plays an important role in regulating inflammatory responses. This review summarizes the functions of ISG15 in different inflammatory diseases. On the one hand, ISG15 precisely regulates the activity of signaling proteins through its intracellular modification function, thereby affecting the type I interferon signaling pathway; on the other hand, free extracellular ISG15 can act as a cytokine, activating immune cells and exacerbating inflammatory responses. We further explored the specific mechanisms of ISG15 in skin inflammation, cardiovascular inflammation, neuroinflammation, and other types of inflammation and analyzed the limitations of current studies. Finally, this study highlights the potential value of targeting the ISG15 pathway as a new strategy for the treatment of inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.